Fairvalue-Calculator Fairvalue-Calculator
EN DE

Genomtec S.A (GMT) Fair Value & Analysis

Healthcare · PL · Market cap 74.4M PLN

Price4.71 PLN
Fair Value2.27 PLN
Upside-51.8%
Quality92/100
Evidence: Low Range 1.70 PLN – 2.84 PLN

Fair value as of: Jun 24, 2026

✦ Find undervalued quality stocks — 34,000+ analysed Find stocks →

Analysis

Genomtec S.A (GMT) currently trades at 4.71 PLN, while our model-based Fair Value estimate is 2.27 PLN — implying the stock looks roughly 51.8% overvalued today. We read business quality at 92/100 (high quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: low).

About the company

Genomtec S.A. researches and develops a mobile point of care genetic testing platform for the clinical diagnostics market in Poland. The company's flagship project is the Genomtec ID, a diagnostic platform that offer mobile genetic diagnosis to patients through streamlined nucleic acid amplification technology (SNAAT) to detect viruses, bacteria, and fungi, as well as genetic mutations by analysis of biological material of patients using swabs, urine, and saliva. It also develops SNAAT chemistry for mutation detection in oncology. In addition, the company develops and commercializes tests used in the detection of viral infectious diseases and other areas. Genomtec S.A. was incorporated in 2008 and is based in Wroclaw, Poland.

Open the full interactive analysis →

Similar stocks

Abbott Laboratories, (ABT) -9% Stryker Corporation (S1YK34) -45% Medtronic plc (MDT) -7% Boston Scientific Corporation (B1SX34) -5% Edwards Lifesciences Corporation (EW) -52% Siemens Healthineers AG (SEMHF) +11%

Frequently asked questions

Is Genomtec S.A (GMT) undervalued?
As of Jun 24, 2026, our model estimates a fair value of 2.27 PLN versus a price of 4.71 PLN — about −52% (overvalued). Model-based estimate, not financial advice.
What is the fair value of GMT?
Our 21-model fair value for Genomtec S.A is 2.27 PLN (as of Jun 24, 2026), built from audited fundamentals. The current price is 4.71 PLN.
What is the quality score of GMT?
Genomtec S.A has a Quality Score of 92/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.